Treatment with Anti-HMGB1 Monoclonal Antibody Does Not Affect Lupus Nephritis in MRL/lpr Mice

High mobility group box 1 (HMGB1) is a nuclear DNA binding protein that acts as an alarmin when secreted. HMGB1 is increased in systemic lupus erythematosus and might represent a potential therapeutic target. We investigated whether treatment with an anti-HMGB1 antibody affects the development of lupus nephritis in MRL/lpr mice. Seven-week-old MRL/lpr mice were injected intraperitoneally twice weekly for 10 wks with 50 µg monoclonal anti-HMGB1 (2G7, mouse IgG2b) (n = 12) or control antibody (n = 11). Control MRL/MPJ mice (n = 10) were left untreated. Every 2 wks, blood was drawn and urine was collected at wk 7, 11 and 17. Mice were sacrificed at 17 wks for complete disease evaluation. Plasma HMGB1 and anti-HMGB1 levels were increased in MRL/lpr mice compared with control MRL/MPJ mice. There were no differences in albuminuria, urine HMGB1 and plasma levels of complement C3, anti-dsDNA and proinflammatory cytokines between untreated and treated mice at any time point. Lupus nephritis of mice treated with anti-HMGB1 monoclonal antibody (mAb) was classified as class III (n = 3) and class IV (n = 9), while mice treated with control mAb were classified as class II (n = 4), class III (n = 2) and class IV (n = 5). IgG and C3 deposits in kidneys were similar in mice treated with anti-HMGB1 mAb or control mAb. In conclusion, treatment with monoclonal anti-HMGB-1 antibody 2G7 does not affect development of lupus nephritis, disease progression or proinflammatory cytokine levels in MRL/lpr mice. This result indicates that blocking of HMGB1 by this neutralizing antibody does not affect lupus nephritis in MRL/lpr mice.

[1]  S. Xiong,et al.  Extracellular, but not intracellular HMGB1, facilitates self-DNA induced macrophage activation via promoting DNA accumulation in endosomes and contributes to the pathogenesis of lupus nephritis. , 2015, Molecular immunology.

[2]  T. Billiar,et al.  Anti-HMGB1 Monoclonal Antibody Ameliorates Immunosuppression after Peripheral Tissue Trauma: Attenuated T-Lymphocyte Response and Increased Splenic CD11b+Gr-1+ Myeloid-Derived Suppressor Cells Require HMGB1 , 2015, Mediators of inflammation.

[3]  K. Tracey,et al.  MD-2 is required for disulfide HMGB1–dependent TLR4 signaling , 2015, The Journal of experimental medicine.

[4]  Q. Yang,et al.  High‐Mobility Group Box 1 Inhibition Alleviates Lupus‐Like Disease in BXSB Mice , 2014, Scandinavian journal of immunology.

[5]  D. Musumeci,et al.  An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. , 2014, Pharmacology & therapeutics.

[6]  V. Pavlov,et al.  HMGB1 mediates splenomegaly and expansion of splenic CD11b+ Ly-6Chigh inflammatory monocytes in murine sepsis survivors , 2013, Journal of internal medicine.

[7]  M. Lotze,et al.  HMGB1: The Central Cytokine for All Lymphoid Cells , 2013, Front. Immunol..

[8]  T. Hibi,et al.  Role of high mobility group box chromosomal protein 1 in ischemia-reperfusion injury in the rat small intestine. , 2012, The Journal of surgical research.

[9]  B. Volpe,et al.  HMGB1 Mediates Cognitive Impairment in Sepsis Survivors , 2012, Molecular medicine.

[10]  K. Tracey,et al.  Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release , 2012, The Journal of experimental medicine.

[11]  M. V. van Dijk,et al.  Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations , 2012, Arthritis Research & Therapy.

[12]  G. V. van Dam,et al.  Targeted Folate Receptor β Fluorescence Imaging as a Measure of Inflammation to Estimate Vulnerability Within Human Atherosclerotic Carotid Plaque , 2012, The Journal of Nuclear Medicine.

[13]  T. Shimazu,et al.  Systemic Involvement of High-Mobility Group Box 1 Protein and Therapeutic Effect of Anti–High-Mobility Group Box 1 Protein Antibody in a Rat Model of Crush Injury , 2012, Shock.

[14]  J. Hutcheson,et al.  Murine lupus strains differentially model unique facets of human lupus serology , 2012, Clinical and experimental immunology.

[15]  K. Tracey,et al.  Redox Modification of Cysteine Residues Regulates the Cytokine Activity of High Mobility Group Box-1 (HMGB1) , 2012, Molecular medicine.

[16]  K. Tracey,et al.  Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis , 2012, Arthritis Research & Therapy.

[17]  Y. Jiao,et al.  Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus , 2012, Rheumatology International.

[18]  U. Andersson,et al.  Monoclonal Anti-HMGB1 (High Mobility Group Box Chromosomal Protein 1) Antibody Protection in Two Experimental Arthritis Models , 2011, Molecular medicine.

[19]  C. Kallenberg,et al.  High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus , 2011, Arthritis research & therapy.

[20]  K. Tracey,et al.  HMGB1 is a therapeutic target for sterile inflammation and infection. , 2011, Annual review of immunology.

[21]  Huan Yang,et al.  Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. , 2010, Arthritis and rheumatism.

[22]  P. Limburg,et al.  HMGB1 in systemic lupus Erythematosus: Its role in cutaneous lesions development. , 2010, Autoimmunity reviews.

[23]  D. Yin,et al.  TLR4 Mediates Early Graft Failure After Intraportal Islet Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  S. Akira,et al.  A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release , 2010, Proceedings of the National Academy of Sciences.

[25]  Xiang Chen,et al.  Expression of High Mobility Group Box Chromosomal Protein 1 and Its Modulating Effects on Downstream Cytokines in Systemic Lupus Erythematosus , 2010, The Journal of Rheumatology.

[26]  I. Ito,et al.  Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity , 2009, Modern rheumatology.

[27]  M. Zamai,et al.  Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. , 2007, Chemistry & biology.

[28]  L. Audoly,et al.  Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE , 2007, Nature Immunology.

[29]  U. Andersson,et al.  HMGB1‐secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay , 2007, Journal of leukocyte biology.

[30]  M. Haslbeck,et al.  Factors masking HMGB1 in human serum and plasma , 2007, Journal of leukocyte biology.

[31]  K. Tracey,et al.  Role of HMGB1 in apoptosis-mediated sepsis lethality. , 2006, The Journal of experimental medicine.

[32]  D. Bullard,et al.  Review of Autoimmune (Lupus-like) Glomerulonephritis in Murine Models , 2006, Ultrastructural pathology.

[33]  M. Bianchi,et al.  HMG proteins: dynamic players in gene regulation and differentiation. , 2005, Current opinion in genetics & development.

[34]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Kidney international.

[35]  K. Tracey,et al.  Reversing established sepsis with antagonists of endogenous high-mobility group box 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Harris,et al.  Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. , 2003, Arthritis and rheumatism.

[37]  M. Yamakuchi,et al.  High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. , 2003, Arthritis and rheumatism.

[38]  Jun Yu Li,et al.  High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. , 2002, Arthritis and rheumatism.

[39]  D. Kono,et al.  Genetics of systemic autoimmunity and glomerulonephritis in mouse models of lupus. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[41]  V. Kelley,et al.  Interaction of mutant lpr gene with background strain influences renal disease. , 1985, Clinical immunology and immunopathology.

[42]  D. Isenberg,et al.  Systemic lupus erythematosus , 1956, The Lancet.

[43]  T. Billiar,et al.  Anti-HMGB 1 Monoclonal Antibody Ameliorates Immunosuppression after Peripheral Tissue Trauma : Attenuated T-Lymphocyte Response and Increased Splenic CD 11 b + Gr-1 + Myeloid-Derived Suppressor Cells Require HMGB 1 , 2015 .